@article{c11895e7a93f421887894f84a8d133cc,
title = "Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol",
keywords = "SARS-CoV-2, COVID-19, Homologous vaccination regimen, Heterologous vaccine regimen, randomized clinical trial, Ad26.Cov2.S, BNT162.b2, mRNA1273 & nbsp;, REACTOGENICITY",
author = "Sablerolles, {Roos S G} and Abraham Goorhuis and GeurtsvanKessel, {Corine H} and {de Vries}, {Rory D} and Huckriede, {Anke L W} and Koopmans, {Marion P G} and Melvin Lafeber and Postma, {Douwe F} and {van Baarle}, Debbie and Visser, {Leo G} and Dalm, {Virgil A S H} and Kootstra, {Neeltje A} and Rietdijk, {Wim J R} and {van der Kuy}, {P Hugo M}",
year = "2021",
month = sep,
day = "24",
doi = "10.3389/fimmu.2021.753319",
language = "English",
volume = "12",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media SA",
}